A5023099227- Hematopoietic Stem Cell Transplantation
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- Acute Lymphoblastic Leukemia research
- Mesenchymal stem cell research
- Acute Myeloid Leukemia Research
- Childhood Cancer Survivors' Quality of Life
- CAR-T cell therapy research
- Immune Response and Inflammation
- Renal Transplantation Outcomes and Treatments
- Pancreatic and Hepatic Oncology Research
- Virus-based gene therapy research
- Neutropenia and Cancer Infections
- Pancreatic function and diabetes
- Multiple Myeloma Research and Treatments
- Histone Deacetylase Inhibitors Research
- IL-33, ST2, and ILC Pathways
- Clinical Nutrition and Gastroenterology
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cytomegalovirus and herpesvirus research
- RNA Interference and Gene Delivery
- Autoimmune and Inflammatory Disorders Research
- Chronic Lymphocytic Leukemia Research
- Neonatal Respiratory Health Research
Icahn School of Medicine at Mount Sinai
2016-2025
Tisch Cancer Institute
2015-2025
Mount Sinai Hospital
2018-2025
University of Oklahoma Health Sciences Center
2024
Children's Healthcare of Atlanta
2024
National Institutes of Health
2024
University of Central Oklahoma
2024
Tisch Hospital
2015-2022
Cancer Institute (WIA)
2019
Mount Sinai Hospital
2014-2018
Highlights•Staging GVHD symptoms varies among BMT centers because of different practices.•Different staging practices make comparing results between studies difficult.•Standardized detailed guidance was developed by a consortium.•Increased uniformity may improve clinical trial reproducibility.AbstractAcute graft-versus-host disease (GVHD) remains leading cause morbidity and nonrelapse mortality after allogeneic hematopoietic cell transplantation. The greatly transplant is frequently not...
The ability of allogeneic bone marrow transplantation to cure chronic myeloid leukemia (CML) is due both the conditioning regimen and antileukemic effects lymphocytes in grafted marrow. We studied interferon alfa-2b infusions mononuclear cells from donor induce a graft-versus-leukemia reaction patients with CML relapse after transplantation.
Next-generation sequencing of the hypervariable V3 region 16s rRNA gene isolated from serial stool specimens collected 31 patients receiving allogeneic stem cell transplantation (SCT) was performed to elucidate variations in composition intestinal microbiome course SCT. Metagenomic analysis complemented by strain-specific enterococcal PCR and indirect assessment bacterial load liquid chromatography-tandem mass spectrometry urinary indoxyl sulfate. At time admission, showed a predominance...
No plasma biomarkers are associated with the response of acute graft-versus-host disease (GVHD) to therapy after allogeneic hematopoietic stem-cell transplantation.We compared 12 in obtained a median 16 days initiation from 10 patients complete by day 28 and progressive GVHD during therapy. The lead biomarker, suppression tumorigenicity 2 (ST2), was measured at beginning treatment for 381 first month transplantation three independent sets totaling 673 determine association this biomarker...
Several international recommendations address the assessment of graft-versus-host disease (GvHD) after hematopoietic cell transplantation (HCT). This position statement by GvHD experts from European Society for Blood and Marrow Transplantation (EBMT), National Institutes Health (NIH) Center International Transplant Research (CIBMTR) reviews existing guidelines both acute chronic GvHD, addresses potential confusions that arise in daily practice proposes consensus definitions many key terms....
Highlights•High-risk graft-versus-host disease patients are less likely to respond steroids than standard-risk patients.•Patients with high-risk have higher risks of mortality and transplant-related patients.•Refined risk score better predicts outcomes published scores.•Patients candidates for novel treatment approaches.•Patients studies investigating toxic therapy.AbstractTo develop a acute (GVHD) score, we examined the GVHD clinical stage grade 1723 at onset systemic steroids. Using...
BACKGROUND. No laboratory test can predict the risk of nonrelapse mortality (NRM) or severe graft-versus-host disease (GVHD) after hematopoietic cellular transplantation (HCT) prior to onset GVHD symptoms.
Severe (grade 3-4) acute graft-versus-host disease (AGVHD) is a major cause of death after unrelated-donor (URD) hematopoietic cell transplant (HCT), resulting in particularly high mortality HLA-mismatched transplantation. There are no approved agents for AGVHD prevention, underscoring the critical unmet need novel therapeutics. ABA2 was phase II trial to rigorously assess safety, efficacy, and immunologic effects adding T-cell costimulation blockade with abatacept calcineurin inhibitor...
More than 40000 hematopoietic cell transplants (HCTs) are performed worldwide each year. With improvements in transplant technology, larger numbers of recipients survive free the disease for which they were transplanted. However, there late complications that can cause substantial morbidity. Many survivors no longer under care centers, and many community health providers may be unfamiliar with matters relevant to HCT. The Center International Blood Marrow Transplant Research (CIBMTR),...
Acute graft-versus-host disease (GVHD) and leukemic relapse remain the two major obstacles to successful outcomes after allogeneic bone marrow transplantation (BMT). Recent studies have demonstrated that loss of gastrointestinal tract integrity, specifically translocation LPS into systemic circulation, is critical induction cytokine dysregulation contributes GVHD. Using a mouse BMT model, we studied effects direct antagonism on GVHD severity graft-versus-leukemia (GVL) activity....
Acute graft-versus-host disease (GVHD) and leukemic relapse are the two major obstacles to successful outcomes after allogeneic bone marrow transplantation (BMT), an effective therapy for hematological malignancies. Several studies have demonstrated that dysregulation of proinflammatory cytokines loss gastrointestinal tract integrity contribute GVHD, whereas donor cytotoxic responses critical graft-versus-leukemia (GVL) preservation. Suberoylanilide hydroxamic acid (SAHA) is currently in...
Histone deacetylase (HDAC) inhibitors are antitumor agents that also have antiinflammatory properties. However, the mechanisms of their immunomodulatory functions not known. We investigated action 2 HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA) and ITF 2357, on mouse DC responses. Pretreatment DCs with significantly reduced TLR-induced secretion proinflammatory cytokines, suppressed expression CD40 CD80, in vitro vivo allostimulatory responses induced by DCs. In addition, injection...